Watson to begin distribution of generic Biaxin

CORONA, Calif. Watson Pharmaceuticals has begun launching its new product, a generic form of Abbott’s antibiotic Biaxin XL. The drug is indicated to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

The generic, clarithromycin extended-release, will be available in a 500 mg tablet strength. The patent infringement case impeding Watson from launching the generic was dismissed on July 12.

For the 12-months ending September 2007, Biaxin XL and its generic equivalents had total U.S. sales of approximately $200 million, according to IMS Health data.